Mode
Text Size
Log in / Sign up

Hospital treatment for heroin use disorder reduced inflammatory markers and addiction scores in a prospective cohortHeroin Addiction Treatment Works When Inflammation Drops

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that treatment in this cohort reduced inflammatory markers and symptom scores, but duration of use and high neopterin predicted poorer outcomes.

This prospective observational cohort study investigated neurotoxic processes and psychiatric symptoms in patients with heroin use disorder who sought treatment at a hospital, compared against a healthy control group. The specific sample size was not reported, and the study phase was not detailed in the available data. The primary focus was on neurotoxic processes, while secondary outcomes included levels of neopterin, tryptophan, kynurenine, and various cytokines, as well as Addiction Profile Index and Symptom Checklist-90-Revised scores.

Following treatment, the heroin use disorder group demonstrated a statistically significant decrease in neopterin levels (p = 0.021) and tumor necrosis factor-alpha (TNF-α) levels (p < 0.05). In contrast, no significant changes were observed for interleukin-6 (IL-6) and interferon-gamma (IFN-γ) levels (p > 0.05). Treatment was also associated with a marked decrease in Addiction Profile Index (API-K) total scores (p < 0.001). Improvements were noted in Symptom Checklist-90-Revised general symptom level and subscales, although specific p-values for these outcomes were not reported.

Factors negatively affecting treatment success were identified, with the duration of use and high baseline neopterin levels emerging as the strongest predictors (p = 0.028 and p = 0.020, respectively). Safety data, including adverse events, tolerability, and discontinuations, were not reported. The study limitations include the lack of reported sample size, follow-up duration, and specific p-values for some secondary outcomes, which restricts the precision of the effect estimates.

Imagine a patient struggling with heroin use disorder. They want to get better, but their brain feels foggy and their mood stays low. This isn't just in their head. Their body is fighting a quiet battle.

Current treatments focus on stopping the drug. But they often miss the hidden fire burning inside. That fire is inflammation. It hurts the brain and makes recovery harder.

The Surprising Shift

Doctors used to think addiction was only a habit or a mental problem. We now know it changes the body too. This new research shows that high levels of a marker called neopterin block healing.

But here's the twist. When patients stop using heroin and get proper care, that marker drops. As it drops, their mental health improves. The body and mind heal together.

Think of your immune system like a security guard. Sometimes, this guard gets too excited and starts attacking healthy parts of the brain. This is what happens with heroin use.

The body makes a chemical called neopterin. High levels mean the guard is overactive. This creates a toxic environment for brain cells. It is like a traffic jam where no one can move.

Researchers followed patients at a hospital who were seeking treatment. They compared these patients to healthy people who never used drugs.

They took blood samples before and after treatment. They measured three key chemicals: tryptophan, kynurenine, and neopterin. They also tracked how severe the addiction was and how patients felt emotionally.

The most important result was clear. Neopterin levels went down significantly after treatment. This drop matched the improvement in mental health scores.

Patients also saw a decrease in another inflammatory marker called TNF-α. This is a protein that causes swelling and pain in the body.

The Catch

Not all markers changed. Levels of IL-6 and IFN-γ stayed the same. This tells us that some parts of the immune system are harder to fix than others.

This doesn't mean this treatment is available yet.

The study also found two big hurdles. The longer someone used heroin, the harder it was to recover. High starting levels of neopterin also made recovery slower. These factors predicted who would struggle the most.

Scientists say this fits with what we know about brain health. Chronic inflammation damages neurons over time. Fixing the chemical balance helps the brain repair itself.

This approach looks at the whole person. It treats the body and the mind at the same time. This is a smarter way to handle complex addictions.

If you or a loved one is struggling, know that your body is trying to heal. Reducing inflammation is a key part of that process.

Talk to your doctor about how your body is responding to treatment. Ask if they track inflammation markers. Understanding these numbers can help you stay motivated.

This study had some limits. It looked at patients at one specific hospital. The group size was not huge. Also, the study was observational, meaning it watched what happened without changing anything.

More research is needed to confirm these findings. Scientists want to test if lowering neopterin directly helps patients. They are also looking at new drugs that might calm the immune system.

Until then, the message is simple. Recovery takes time. Your body needs support to clear out the inflammation. With patience and the right care, healing is possible.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
AimThis study investigated the effects of tryptophan (TRP) metabolism, kynurenine pathway (KP) and neopterin levels in heroin use disorder (HUD) in relation to neurotoxicity, treatment processes and psychiatric recovery.MethodThe study groups consisted of patients with HUD who sought treatment at the hospital and received treatment, and a healthy control (C) group. The levels of neopterin, tryptophan and kynurenine in the participants’ serum were determined, and the pre- and post-treatment results in the groups were compared with the controls.ResultsNeopterin levels, reflecting immune system activation, were observed to decrease in HUD group after treatment (p = 0.021). Similarly, a decrease in levels of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, was also detected after treatment (p < 0.05). However, changes in interleukin-6 (IL-6) and interferon-gamma (IFN-γ) levels were not found to be significant (p > 0.05). The total scores of the Addiction Profile Index (API-K), which measures the severity of addiction, decreased significantly after treatment (p < 0.001). At the same time, improvement was observed in the general symptom level (GSI) and all subscales (including depression, anxiety, obsessive-compulsive disorders, and somatization) of the Symptom Checklist-90-Revised (SCL-90-R) scale, which assesses general psychopathology. Regression analyses revealed that the two strongest factors negatively affecting treatment success in the HUD group were duration of use (p = 0.028) and high neopterin levels (p = 0.020).ConclusionThis study highlights the critical role of immunological and neuroinflammatory processes in the success of HUD treatment. The findings indicate that biochemical recovery progresses in parallel with psychiatric recovery during treatment, and that changes in the KYN/TRP ratio and IL-6 levels have strong diagnostic and prognostic value. Neopterin, kynurenine, and tryptophan, on the other hand, have moderate prognostic value.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.